​​​​​​​PsA Treatment Options Expand

• by Kathryn Wighton

• March 9, 2026

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

• by Nada Elbuluk, April W. Armstrong, Ronald Vender, Tina Bhutani, Lawrence Green, Laura K. Ferris, Vivian Laquer, Angela Moore, Jamie Weisman, Wenwen Zhang, Warren Winkelman, Melinda J. Gooderham

• May 16, 2026

Multi-Omics Insights into Spondyloarthritis and Psoriatic Arthritis: Integrating Genomics, Transcriptomics, Proteomics, and the Microbiome for Immunological and Clinical Translation

• by Zhu, Minshun , Li, Renzhong , Wu, Sanbing , Chen, Jiaping , Sun, Kui

• April 28, 2026

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.

• by Andrea Surnit

• May 22, 2026

• 4 min